Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2017 pubmed 6 citations

The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage.

Christiansen. Stig Hill SH; Zhang. Xianwei X; Juul-Madsen. Kristian K; Hvam. Michael Lykke ML; Vad. Brian Stougaard BS; Behrens. Manja Annette MA; Thygesen. Ida Lysgaard IL; Jalilian. Babak B; Pedersen. Jan Skov JS; Howard. Kenneth A KA; Otzen. Daniel E DE; Vorup-Jensen. Thomas T

Key Findings

  • GA rapidly kills primary human T‑lymphocytes and, to a lesser extent, monocytes
  • LL‑37 also kills human leukocytes and shares the same charge‑and‑amphipathic properties as GA
  • Cytotoxicity of both peptides requires sialic acid on the cell membrane and involves oligomer formation
  • Cell membrane debris (CD45+ fragments) is generated during killing, detectable even at low GA concentrations

Practical Outcomes

  • If you’re experimenting with cationic, amphipathic peptides like LL‑37 for health benefits, be aware they can damage your own immune cells, especially at higher doses. This research suggests limiting exposure and monitoring immune markers, rather than assuming such peptides are universally safe or beneficial.

Summary

The study shows that the MS drug glatiramer acetate (GA) and the natural peptide LL‑37, both positively charged and amphipathic, can quickly kill human immune cells by damaging their membranes in a way that needs sialic acid. This cell‑killing effect is linked to the peptides forming small clusters (oligomers). For DIY health enthusiasts, it signals that using similar cationic peptides could unintentionally suppress immune function if not carefully dosed.

Abstract

The formulation glatiramer acetate (GA) is widely used in therapy of multiple sclerosis. GA consists of random copolymers of four amino acids, in ratios that produce a predominantly positive charge and an amphipathic character. With the extraordinary complexity of the drug, several pharmacological modes-of-action were suggested, but so far none, which rationalizes the cationicity and amphipathicity as part of the mode-of-action. Here, we report that GA rapidly kills primary human T lymphocytes and, less actively, monocytes. LL-37 is a cleavage product of human cathelicidin with important roles in innate immunity. It shares the positive charge and amphipathic character of GA, and, as shown here, also the ability to kill human leukocyte. The cytotoxicity of both compounds depends on sialic acid in the cell membrane. The killing was associated with the generation of CD45+ debris, derived from cell membrane deformation. Nanoparticle tracking analysis confirmed the formation of such debris, even at low GA concentrations. Electric cell-substrate impedance sensing measurements also recorded stable alterations in T lymphocytes following such treatment. LL-37 forms oligomers through weak hydrophobic contacts, which is critical for the lytic properties. In our study, SAXS showed that GA also forms this type of contacts. Taken together, our study offers new insight on the immunomodulatory mode-of-action of positively charged co-polymers. The comparison of LL-37 and GA highlights a consistent requirement of certain oligomeric and chemical properties to support cytotoxic effects of cationic polymers targeting human leukocytes.

Study Information

Provider

pubmed

Year

2017

Date

2017-01-05T00:00:00.000Z

DOI

10.1016/j.bbamem.2017.01.001

Citations

6

References

63